Nabilone (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Nabilone" in English language version.

refsWebsite

Global rank English rank

19nih.gov

4^th place

11doi.org

2^nd place

3semanticscholar.org

11^th place

8^th place

2web.archive.org

1^st place

2pharmatimes.com

low place

1springer.com

274^th place

309^th place

1drugs.com

399^th place

333^rd place

1fda.gov

447^th place

338^th place

1handle.net

102^nd place

76^th place

1medicines.org.uk

3,823^rd place

2,387^th place

1canada.ca

1,712^th place

1,063^rd place

1thepharmaletter.com

low place

1medicalmarijuana.eu

low place

canada.ca

"Nabilone". Health Canada. Retrieved 2023-07-01.

doi.org

Fine PG, Rosenfeld MJ (2013). "The endocannabinoid system, cannabinoids, and pain". Rambam Maimonides Medical Journal (Review). 4 (4): e0022. doi:10.5041/RMMJ.10129. PMC 3820295. PMID 24228165.
Wissel J, Haydn T, Müller J, Brenneis C, Berger T, Poewe W, Schelosky LD (October 2006). "Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial". Journal of Neurology (Research article). 253 (10): 1337–41. doi:10.1007/s00415-006-0218-8. PMID 16988792. S2CID 24206300.
Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, Buckley N, Farrell M (February 2018). "The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews". Current Neurology and Neuroscience Reports. 18 (2): 8. doi:10.1007/s11910-018-0814-x. hdl:2123/18910. PMID 29442178. S2CID 3375801.
Lynch ME, Campbell F (November 2011). "Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials". British Journal of Clinical Pharmacology. 72 (5): 735–44. doi:10.1111/j.1365-2125.2011.03970.x. PMC 3243008. PMID 21426373.
Bedi G, Cooper ZD, Haney M (September 2013). "Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers". Addiction Biology. 18 (5): 872–81. doi:10.1111/j.1369-1600.2011.00427.x. PMC 3335956. PMID 22260337.
Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, Harding M, Kerr DJ, Soukop M, Kaye SB (April 1988). "A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues". European Journal of Cancer & Clinical Oncology (Randomized controlled trial). 24 (4): 685–9. doi:10.1016/0277-5379(88)90300-8. PMID 2838294.
Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S (November 2015). "Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy". The Cochrane Database of Systematic Reviews. 2021 (11): CD009464. doi:10.1002/14651858.CD009464.pub2. PMC 6931414. PMID 26561338.
Pini LA, Guerzoni S, Cainazzo MM, Ferrari A, Sarchielli P, Tiraferri I, Ciccarese M, Zappaterra M (November 2012). "Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial". The Journal of Headache and Pain. 13 (8): 677–84. doi:10.1007/s10194-012-0490-1. PMC 3484259. PMID 23070400.
Sholler DJ, Huestis MA, Amendolara B, Vandrey R, Cooper ZD (December 2020). "Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids". Pharmacol Biochem Behav. 199: 173059. doi:10.1016/j.pbb.2020.173059. PMC 7725960. PMID 33086126.
Zhornitsky S, Pelletier J, Assaf R, Giroux S, Li CR, Potvin S (January 2021). "Acute effects of partial CB1 receptor agonists on cognition - A meta-analysis of human studies". Prog Neuropsychopharmacol Biol Psychiatry. 104: 110063. doi:10.1016/j.pnpbp.2020.110063. PMID 32791166. S2CID 221092170.
Lutge EE, Gray A, Siegfried N (April 2013). "The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS". The Cochrane Database of Systematic Reviews (4): CD005175. doi:10.1002/14651858.CD005175.pub3. PMID 23633327.

drugs.com

"Nabilone Advanced Patient Information".

fda.gov

accessdata.fda.gov

"Nabilone label" (PDF). FDA. May 2006.

handle.net

hdl.handle.net

Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, Buckley N, Farrell M (February 2018). "The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews". Current Neurology and Neuroscience Reports. 18 (2): 8. doi:10.1007/s11910-018-0814-x. hdl:2123/18910. PMID 29442178. S2CID 3375801.

medicalmarijuana.eu

"Cannabis Laws & Scheduling in Europe - MedicalMarijuana.eu". MedicalMarijuana.eu. Archived from the original on 18 November 2016. Retrieved 17 November 2016.

medicines.org.uk

"Nabilone Summary of Product Characteristics (SPC) - (eMC)". UK Electronic Medicines Compendium. August 2014. Archived from the original on 2017-12-22. Retrieved 2016-11-17.

nih.gov

pubmed.ncbi.nlm.nih.gov

Fine PG, Rosenfeld MJ (2013). "The endocannabinoid system, cannabinoids, and pain". Rambam Maimonides Medical Journal (Review). 4 (4): e0022. doi:10.5041/RMMJ.10129. PMC 3820295. PMID 24228165.
Wissel J, Haydn T, Müller J, Brenneis C, Berger T, Poewe W, Schelosky LD (October 2006). "Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial". Journal of Neurology (Research article). 253 (10): 1337–41. doi:10.1007/s00415-006-0218-8. PMID 16988792. S2CID 24206300.
Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, Buckley N, Farrell M (February 2018). "The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews". Current Neurology and Neuroscience Reports. 18 (2): 8. doi:10.1007/s11910-018-0814-x. hdl:2123/18910. PMID 29442178. S2CID 3375801.
Lynch ME, Campbell F (November 2011). "Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials". British Journal of Clinical Pharmacology. 72 (5): 735–44. doi:10.1111/j.1365-2125.2011.03970.x. PMC 3243008. PMID 21426373.
Bedi G, Cooper ZD, Haney M (September 2013). "Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers". Addiction Biology. 18 (5): 872–81. doi:10.1111/j.1369-1600.2011.00427.x. PMC 3335956. PMID 22260337.
Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, Harding M, Kerr DJ, Soukop M, Kaye SB (April 1988). "A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues". European Journal of Cancer & Clinical Oncology (Randomized controlled trial). 24 (4): 685–9. doi:10.1016/0277-5379(88)90300-8. PMID 2838294.
Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S (November 2015). "Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy". The Cochrane Database of Systematic Reviews. 2021 (11): CD009464. doi:10.1002/14651858.CD009464.pub2. PMC 6931414. PMID 26561338.
"Long-term Nabilone Use: A Review of the Clinical Effectiveness and Safety". CADTH Rapid Response Reports. Oct 2015. PMID 26561692.
Pini LA, Guerzoni S, Cainazzo MM, Ferrari A, Sarchielli P, Tiraferri I, Ciccarese M, Zappaterra M (November 2012). "Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial". The Journal of Headache and Pain. 13 (8): 677–84. doi:10.1007/s10194-012-0490-1. PMC 3484259. PMID 23070400.
Sholler DJ, Huestis MA, Amendolara B, Vandrey R, Cooper ZD (December 2020). "Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids". Pharmacol Biochem Behav. 199: 173059. doi:10.1016/j.pbb.2020.173059. PMC 7725960. PMID 33086126.
Zhornitsky S, Pelletier J, Assaf R, Giroux S, Li CR, Potvin S (January 2021). "Acute effects of partial CB1 receptor agonists on cognition - A meta-analysis of human studies". Prog Neuropsychopharmacol Biol Psychiatry. 104: 110063. doi:10.1016/j.pnpbp.2020.110063. PMID 32791166. S2CID 221092170.
Lutge EE, Gray A, Siegfried N (April 2013). "The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS". The Cochrane Database of Systematic Reviews (4): CD005175. doi:10.1002/14651858.CD005175.pub3. PMID 23633327.

ncbi.nlm.nih.gov

Fine PG, Rosenfeld MJ (2013). "The endocannabinoid system, cannabinoids, and pain". Rambam Maimonides Medical Journal (Review). 4 (4): e0022. doi:10.5041/RMMJ.10129. PMC 3820295. PMID 24228165.
Lynch ME, Campbell F (November 2011). "Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials". British Journal of Clinical Pharmacology. 72 (5): 735–44. doi:10.1111/j.1365-2125.2011.03970.x. PMC 3243008. PMID 21426373.
Bedi G, Cooper ZD, Haney M (September 2013). "Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers". Addiction Biology. 18 (5): 872–81. doi:10.1111/j.1369-1600.2011.00427.x. PMC 3335956. PMID 22260337.
Smith LA, Azariah F, Lavender VT, Stoner NS, Bettiol S (November 2015). "Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy". The Cochrane Database of Systematic Reviews. 2021 (11): CD009464. doi:10.1002/14651858.CD009464.pub2. PMC 6931414. PMID 26561338.
"Long-term Nabilone Use: A Review of the Clinical Effectiveness and Safety". CADTH Rapid Response Reports. Oct 2015. PMID 26561692.
Pini LA, Guerzoni S, Cainazzo MM, Ferrari A, Sarchielli P, Tiraferri I, Ciccarese M, Zappaterra M (November 2012). "Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial". The Journal of Headache and Pain. 13 (8): 677–84. doi:10.1007/s10194-012-0490-1. PMC 3484259. PMID 23070400.
Sholler DJ, Huestis MA, Amendolara B, Vandrey R, Cooper ZD (December 2020). "Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids". Pharmacol Biochem Behav. 199: 173059. doi:10.1016/j.pbb.2020.173059. PMC 7725960. PMID 33086126.

pharmatimes.com

"Valeant returns synthetic cannabinoid to USA". Pharma Times. 17 May 2006.
"FDA turns down Valeant's anti-nausea drug". Pharma Times. 3 January 2006.

semanticscholar.org

api.semanticscholar.org

Wissel J, Haydn T, Müller J, Brenneis C, Berger T, Poewe W, Schelosky LD (October 2006). "Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial". Journal of Neurology (Research article). 253 (10): 1337–41. doi:10.1007/s00415-006-0218-8. PMID 16988792. S2CID 24206300.
Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, Buckley N, Farrell M (February 2018). "The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews". Current Neurology and Neuroscience Reports. 18 (2): 8. doi:10.1007/s11910-018-0814-x. hdl:2123/18910. PMID 29442178. S2CID 3375801.
Zhornitsky S, Pelletier J, Assaf R, Giroux S, Li CR, Potvin S (January 2021). "Acute effects of partial CB1 receptor agonists on cognition - A meta-analysis of human studies". Prog Neuropsychopharmacol Biol Psychiatry. 104: 110063. doi:10.1016/j.pnpbp.2020.110063. PMID 32791166. S2CID 221092170.

springer.com

adisinsight.springer.com

"Nabilone - AdisInsight".

thepharmaletter.com

"Cambridge Labs divests nabilone to Valeant - Pharmaceutical industry n". The Pharma Letter. February 27, 2007.

web.archive.org

"Nabilone Summary of Product Characteristics (SPC) - (eMC)". UK Electronic Medicines Compendium. August 2014. Archived from the original on 2017-12-22. Retrieved 2016-11-17.
"Cannabis Laws & Scheduling in Europe - MedicalMarijuana.eu". MedicalMarijuana.eu. Archived from the original on 18 November 2016. Retrieved 17 November 2016.